Timothy Khater, MD
Ophthalmology · Lubbock, TXNPI 1669476255
Payments from drug & device makers
Across 446 payments — averaging $42.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$5K
- Alcon$3K
- Glaukos Corporation$3K
- AbbVie$2K
- Ivantis, Inc$1K
- Ocular Therapeutix, Inc.$1K
- plus $3K from 28 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$6123%
- Travel & lodging$3,28017%
- Food & beverage$14,79878%
- Entertainment$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 83 | $5,018 |
| Alcon | 47 | $3,265 |
| Glaukos Corporation | 45 | $2,938 |
| AbbVie(2 entities) | 93 | $2,331 |
| Ivantis, Inc | 18 | $1,067 |
| Ocular Therapeutix, Inc. | 46 | $1,012 |
| Sight Sciences, Inc. | 28 | $678 |
| Bausch & Lomb Americas Inc. | 11 | $328 |
| Rxsight Inc | 5 | $253 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $217 |
| Optos, Inc. | 5 | $211 |
| Astellas Pharma US Inc | 4 | $186 |
| Genentech USA, Inc. | 4 | $185 |
| Sun Pharmaceutical Industries Inc. | 2 | $185 |
| Regeneron Healthcare Solutions, Inc. | 4 | $142 |
| Aerie Pharmaceuticals, Inc. | 8 | $140 |
| Iridex Corporation | 2 | $109 |
| NEW World Medical,inc. | 4 | $86 |
| ANI Pharmaceuticals, Inc. | 4 | $81 |
| Alimera Sciences, Inc. | 2 | $70 |
| Shire North American Group Inc | 3 | $64 |
| Mckesson Medical-surgical, Inc. | 1 | $50 |
| Dompe US, Inc. | 2 | $44 |
| Amgen | 2 | $43 |
| Lensar, Inc. | 2 | $42 |
| Biotissue Holdings Inc. | 1 | $41 |
| Beaver-visitec International, Inc. | 1 | $38 |
| QOL Medical, LLC | 1 | $38 |
| Carl Zeiss Meditec USA, Inc. | 2 | $37 |
| Novartis | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,593
- Tecnis Multifocal Family of 1-piece IOLS$1,589
- Tecnis Symfony IOL$1,589
- iStent Trabecular Micro-Bypass Stent System$1,134
- iStent inject Trabecular Micro-Bypass Stent System$1,134
- DEXTENZA$900
- Hydrus Microstent$704
- Tecnis IOL$557
- VERITAS Vision System$330
- Wavelight$241
- Whitestar Signature Pro$220
- Tecnis Simplicity$206
- Tecnis Toric 1-piece IOL$205
- AcrySof IQ PanOptix UV IOL$146
- Izervay$121
- BOTOX$118
- SUSVIMO$118
- Centurion$116
- NGENUITY$113
- iStent inject W$112
How this compares
$19,012 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $368,515 |
| LumiganBimatoprost | 272 | $139,295 |
| Prednisolone Acetate | 735 | $36,269 |
| RestasisCyclosporine | 36 | $35,261 |
| VyzultaLatanoprostene Bunod | 40 | $17,040 |
| XiidraLifitegrast | 13 | $15,788 |
| Cyclosporine | 19 | $14,427 |
| MoxifloxacinMoxifloxacin Hcl | 420 | $9,999 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $9,775 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 53 | $8,357 |
| Ketorolac Tromethamine | 441 | $7,642 |
| Loteprednol Etabonate | 44 | $6,842 |
| Travoprost | 42 | $6,773 |
| TafluprostTafluprost/Pf | 27 | $6,371 |
| Latanoprost | 531 | $5,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $44 | $368,51513 claims |
| AbbVieLumigan, Restasis, Combigan | $2,331 | $184,331337 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $328 | $32,82753 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Besivance | $217 | $13,70569 claims |
| AlconSimbrinza | $3,265 | $3,00016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Lubbock
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.